Published in PLoS One on November 22, 2016
Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective. J Diabetes Res (2017) 0.78
Adherence to medication. N Engl J Med (2005) 39.77
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Standards of medical care in diabetes--2014. Diabetes Care (2014) 20.97
Prevalence and control of diabetes in Chinese adults. JAMA (2013) 11.73
Impact of medication adherence on hospitalization risk and healthcare cost. Med Care (2005) 9.62
Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med (2006) 7.54
Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med (2002) 3.90
Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care (2004) 3.31
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia (2004) 3.01
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making (2002) 2.96
The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care (2012) 2.33
Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother (2004) 2.31
Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther (2003) 2.13
The economic and quality of life impact of hypoglycemia. Eur J Health Econ (2005) 1.61
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab (2008) 1.57
The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin (2014) 1.56
Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab (2013) 1.55
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess (2010) 1.53
Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin (2006) 1.44
Non-industrialised countries and affluence. Br Med Bull (2001) 1.42
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med (2011) 1.41
Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res (2007) 1.39
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med (2008) 1.37
Inconsistent use of diabetes medications, diabetes complications, and mortality in older mexican americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care (2003) 1.32
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol (2007) 1.18
The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health (2005) 1.11
Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence (2015) 1.09
The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med (2009) 1.08
Determinants of adherence to diabetes treatment. J Diabetes (2015) 1.06
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs (2003) 1.05
Effective Control of Postprandial Glucose Level through Inhibition of Intestinal Alpha Glucosidase by Cymbopogon martinii (Roxb.). Evid Based Complement Alternat Med (2011) 1.03
Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med (2013) 0.99
Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med (2012) 0.93
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res (2012) 0.93
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid (2010) 0.92
Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin (2006) 0.91
A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab (2010) 0.89
Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence (2015) 0.87
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther (2008) 0.87
Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics (2010) 0.85
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care (2012) 0.83
Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther (2011) 0.83
New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits (2014) 0.81
Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clin Ther (2014) 0.79
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr (2014) 0.78
Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. Clin Diabetes (2014) 0.77
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vasc Health Risk Manag (2014) 0.76
Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diabetes Res Clin Pract (2015) 0.76